We expect investors to focus on the sales numbers of CRISPR Therapeutics’ CRSP sole-marketed product, Casgevy, and other ...

Prime Medicine’s modular editing tech may lower off-target risk, but key data and funding milestones remain ahead. Find out ...

The CRISPR company is laying off about a third of its employees and stopping work on an experimental lupus treatment in a bid ...